Macquarie Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Macquarie Group’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-100,000	Closed	-$3.77M	–	2596
2021 Q1	$3.77M	Hold	100,000	–	–	0.01%	993
2020 Q4	$1.7M	Hold	100,000	–	–	﹤0.01%	1152
2020 Q3	$470K	Hold	100,000	–	–	﹤0.01%	1417
2020 Q2	$610K	Hold	100,000	–	–	﹤0.01%	1309
2020 Q1	$227K	Hold	100,000	–	–	﹤0.01%	1425
2019 Q4	$459K	Hold	100,000	–	–	﹤0.01%	1417
2019 Q3	$388K	Hold	100,000	–	–	﹤0.01%	1428
2019 Q2	$603K	Hold	100,000	–	–	﹤0.01%	1316
2019 Q1	$1.34M	Buy	+100,000	New	+$1.14M	﹤0.01%	1106
2016 Q2	–	Sell	-55,938	Closed	-$2.27M	–	1661
2016 Q1	$2.27M	Buy	55,938 +1,948	+4%	+$67K	﹤0.01%	919
2015 Q4	$2.24M	Buy	53,990 +5,990	+12%	+$201K	﹤0.01%	908
2015 Q3	$739K	Buy	+48,000	New	+$1.03M	﹤0.01%	1181

Macquarie Group's FPRX Position: Q2 2021 in Review

Macquarie Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 100,000 shares — an estimated $3.77M sold.

Macquarie Group first reported a position in FPRX in Q3 2015 and held it in 12 quarters. The position peaked at $3.77M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Macquarie Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Macquarie Group sold 100,000 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $3.77M.
Macquarie Group first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 12 quarters.
Macquarie Group's Five Prime Therapeutics, Inc. position peaked at $3.77M in Q1 2021.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Macquarie Group's 13F filing for Q2 2021, filed 13 Aug 2021.